These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

206 related articles for article (PubMed ID: 9397233)

  • 1. A fresh look at the molecular pharmacology of plasminogen activators: from theory to test tube to clinical outcomes.
    Smalling RW
    Am J Health Syst Pharm; 1997 Nov; 54 Suppl 1():S17-22. PubMed ID: 9397233
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Molecular biology of plasminogen activators: what are the clinical implications of drug design?
    Smalling RW
    Am J Cardiol; 1996 Dec; 78(12A):2-7. PubMed ID: 8990404
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Patency trials with reteplase (r-PA): what do they tell us?
    Bode C; Nordt TK; Peter K; Smalling RW; Runge MS; Kübler W
    Am J Cardiol; 1996 Dec; 78(12A):16-9. PubMed ID: 8990406
    [TBL] [Abstract][Full Text] [Related]  

  • 4. New developments in thrombolytic therapy.
    Collen D; Gold HK
    Adv Exp Med Biol; 1990; 281():333-54. PubMed ID: 2129372
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Randomized comparison of coronary thrombolysis achieved with double-bolus reteplase (recombinant plasminogen activator) and front-loaded, accelerated alteplase (recombinant tissue plasminogen activator) in patients with acute myocardial infarction. The RAPID II Investigators.
    Bode C; Smalling RW; Berg G; Burnett C; Lorch G; Kalbfleisch JM; Chernoff R; Christie LG; Feldman RL; Seals AA; Weaver WD
    Circulation; 1996 Sep; 94(5):891-8. PubMed ID: 8790022
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The role of thrombolytic drugs in the management of myocardial infarction. Comparative clinical trials.
    Weaver WD
    Eur Heart J; 1996 Dec; 17 Suppl F():9-15. PubMed ID: 8960443
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [t-PA in thrombolytic therapy of acute myocardial infarct].
    Rutsch W; Schmutzler H
    Herz; 1994 Dec; 19(6):336-52. PubMed ID: 7843690
    [TBL] [Abstract][Full Text] [Related]  

  • 8. In vitro simulation of therapeutic thrombolysis with microtiter plate clot-lysis assay.
    Stief TW
    Clin Appl Thromb Hemost; 2006 Jan; 12(1):21-32. PubMed ID: 16444431
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Molecular basis of fibrinolysis, as relevant for thrombolytic therapy.
    Collen D; Lijnen HR
    Thromb Haemost; 1995 Jul; 74(1):167-71. PubMed ID: 8578451
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Coronary thrombolysis with clot-selective plasminogen activators.
    Collen D; Bounameaux H
    Herz; 1986 Feb; 11(1):9-15. PubMed ID: 3082731
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Platelet function during and after thrombolytic therapy for acute myocardial infarction with reteplase, alteplase, or streptokinase.
    Moser M; Nordt T; Peter K; Ruef J; Kohler B; Schmittner M; Smalling R; Kübler W; Bode C
    Circulation; 1999 Nov; 100(18):1858-64. PubMed ID: 10545429
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Newer thrombolytic agents.
    Verstraete M
    Ann Acad Med Singap; 1999 May; 28(3):424-33. PubMed ID: 10575530
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Reteplase. A review of its pharmacological properties and clinical efficacy in the management of acute myocardial infarction.
    Noble S; McTavish D
    Drugs; 1996 Oct; 52(4):589-605. PubMed ID: 8891469
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Pharmacological and clinical impact of the unique molecular structure of a new plasminogen activator.
    Smalling RW
    Eur Heart J; 1997 Dec; 18 Suppl F():F11-6. PubMed ID: 9447335
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Platelet function and fibrinolytic agents: two sides of a coin?
    Callahan KP; Malinin AI; Gurbel PA; Alexander JH; Granger CB; Serebruany VL
    Cardiology; 2001; 95(2):55-60. PubMed ID: 11423707
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Spotlight on reteplase in thrombotic occlusive disorders.
    Simpson D; Siddiqui MA; Scott LJ; Hilleman DE
    BioDrugs; 2007; 21(1):65-8. PubMed ID: 17263591
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [New thrombolytic agents in myocardial infarction].
    Charbonnier B; Lang M; Brochier M
    Arch Mal Coeur Vaiss; 1987 Nov; 80(12):1785-91. PubMed ID: 3128222
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Thrombolytic therapy.
    Collen D; Stump DC; Gold HK
    Annu Rev Med; 1988; 39():405-23. PubMed ID: 3130773
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Streptokinase and rt-PA activate platelets by a different way: implications on the rethrombosis rate after their administration in myocardial infarction.
    Parise P; Hauert J; Iorio A; Callegari P; Agnelli G
    J Lab Clin Med; 1995 Feb; 125(2):212-21. PubMed ID: 7531212
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Reteplase: a review of its use in the management of thrombotic occlusive disorders.
    Simpson D; Siddiqui MA; Scott LJ; Hilleman DE
    Am J Cardiovasc Drugs; 2006; 6(4):265-85. PubMed ID: 16913828
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.